Verve Therapeutics Announces Leadership Update
May 31 2024 - 7:00AM
Verve Therapeutics, a clinical-stage biotechnology company
pioneering a new approach to the care of cardiovascular disease
with single-course gene editing medicines, today announced that
Troy Lister, Ph.D., currently serving as Verve’s senior vice
president, research and early development, has been appointed chief
scientific officer (CSO), effective June 21, 2024. Andrew
Bellinger, M.D., Ph.D., who has served as CSO since 2019, will step
down from this role and serve in an advisory capacity.
“Over the past two years, Troy has been a respected colleague
and wonderful leader at Verve, preceded by a longstanding career in
research and development and program and portfolio management. In
his new role as chief scientific officer, Troy will lead our
research efforts as we further advance our pipeline programs, all
of which address a robust set of validated cardiovascular targets
in areas of high unmet need,” said Sekar Kathiresan, M.D.,
co-founder and chief executive officer of Verve Therapeutics. “Troy
inherits a strong research function from Andrew. During his five
years at Verve, Andrew, serving as Chief Scientific Officer and for
a time as Chief Medical Officer, developed Verve’s pipeline,
progressed our preclinical and clinical development programs, and
built a phenomenal scientific team. On behalf of the entire team, I
would like to thank Andrew for all of his contributions to Verve
and to the cardiovascular disease patients we seek to serve.”
Dr. Lister brings more than 15 years of experience in the
biopharmaceutical industry, with extensive work in drug discovery,
research, and development and program and portfolio leadership.
Prior to joining Verve, he served as senior vice president of
research and development at Spero Therapeutics, where he helped
build the research and development organization and led multiple
programs into first-in-human studies and through early clinical
development. Dr. Lister has also held scientific and leadership
roles at the Novartis Institutes for Biomedical Research and
AstraZeneca. He holds a B.Sc. and Ph.D. in Organic Chemistry from
Flinders University, Australia. He completed post-doctoral studies
in bioactive natural product total synthesis at The Scripps
Research Institute with Professor K.C. Nicolaou.
About Verve Therapeutics Verve
Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage genetic
medicines company pioneering a new approach to the care of
cardiovascular disease, potentially transforming treatment from
chronic management to single-course gene editing medicines. The
company’s lead programs – VERVE-101, VERVE-102, and VERVE-201 –
target genes that have been extensively validated as targets for
lowering low-density lipoprotein cholesterol (LDL-C), a root cause
of atherosclerotic cardiovascular disease (ASCVD). VERVE-101 and
VERVE-102 are designed to permanently turn off the PCSK9 gene in
the liver and are being developed initially for heterozygous
familial hypercholesterolemia (HeFH) and ultimately to treat
patients with established ASCVD who continue to be impacted by high
LDL-C levels. VERVE-201 is designed to permanently turn off the
ANGPTL3 gene in the liver and is initially being developed for
homozygous familial hypercholesterolemia (HoFH) and for refractory
hypercholesterolemia where patients still have high LDL-C despite
treatment with maximally-tolerated standard of care therapies. For
more information, please visit www.VerveTx.com.
Cautionary Note Regarding Forward Looking
StatementsThis press release contains “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995 that involve substantial risks and
uncertainties, including statements regarding timing of the CSO
transition and the potential advantages and therapeutic potential
of the company’s programs. All statements, other than statements of
historical facts, contained in this press release, including
statements regarding the company’s strategy, future operations,
future financial position, prospects, plans and objectives of
management, are forward-looking statements. The words “anticipate,”
“believe,” “continue,” “could,” “estimate,” “expect,” “intend,”
“may,” “plan,” “potential,” “predict,” “project,” “should,”
“target,” “will,” “would” and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Any
forward-looking statements are based on management’s current
expectations of future events and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially and adversely from those set forth in, or implied by,
such forward-looking statements. These risks and uncertainties
include, but are not limited to, risks associated with the
company’s limited operating history; the company’s ability to
timely submit and receive approvals of regulatory applications for
its product candidates; advance its product candidates in clinical
trials; initiate, enroll and complete its ongoing and future
clinical trials on the timeline expected or at all; correctly
estimate the potential patient population and/or market for the
company’s product candidates; replicate in clinical trials positive
results found in preclinical studies and/or earlier-stage clinical
trials of VERVE-101, VERVE-102, and VERVE-201; advance the
development of its product candidates under the timelines it
anticipates in current and future clinical trials; obtain, maintain
or protect intellectual property rights related to its product
candidates; manage expenses; and raise the substantial additional
capital needed to achieve its business objectives. For a discussion
of other risks and uncertainties, and other important factors, any
of which could cause the company’s actual results to differ from
those contained in the forward-looking statements, see the “Risk
Factors” section, as well as discussions of potential risks,
uncertainties and other important factors, in the company’s most
recent filings with the Securities and Exchange Commission and in
other filings that the company makes with the Securities and
Exchange Commission in the future. In addition, the forward-looking
statements included in this press release represent the company’s
views as of the date hereof and should not be relied upon as
representing the company’s views as of any date subsequent to the
date hereof. The company anticipates that subsequent events and
developments will cause the company’s views to change. However,
while the company may elect to update these forward-looking
statements at some point in the future, the company specifically
disclaims any obligation to do so.
Investor ContactJen RobinsonVerve Therapeutics,
Inc.jrobinson@vervetx.com
Media ContactAshlea
Kosikowski1ABashlea@1abmedia.com
Verve Therapeutics (NASDAQ:VERV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Verve Therapeutics (NASDAQ:VERV)
Historical Stock Chart
From Sep 2023 to Sep 2024